Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female child of 5 and 6 years of age at the time of vaccination.~* Subjects who received a complete 3-dose vaccination with a DTPa-based combined vaccine according to a 3-5-11 month schedule in line with recommendations in Italy.~* Subjects who received a first dose of a live attenuated measles-mumps-rubella vaccine in the second year of life, in line with recommendations in Italy.~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* Written informed consent obtained from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose.~* Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Previous booster vaccination against tetanus, diphtheria, pertussis and/or poliomyelitis since vaccination in the first two years of life.~* Previous measles, mumps, rubella and/or varicella second dose vaccination.~* Known history of diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella and/or varicella disease.~* Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to study start.~* Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Administration of immunoglobulin and/or any blood products within the three months preceding vaccination or planned administration during the study period.~* Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.~* Occurrence of any of the following adverse events after a previous administration of a DTP vaccine:~  * Hypersensitivity reaction to any component of the vaccine;~ * Encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine;~ * Fever \>= 40°C within 48 hours of vaccination, not due to another identifiable cause;~ * Collapse or shock-like state within 48 hours of vaccination;~ * Convulsions with or without fever, occurring within 3 days of vaccination.~* Residence in the same household as a person high risk for varicella~* The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:~  * Current febrile illness or axillary temperature ≥ 38.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- BOOSTRIX POLIO GROUP (Type: EXPERIMENTAL): Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Boostrix Polio™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Boostrix Polio™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
- TETRAVAC GROUP (Type: ACTIVE_COMPARATOR): Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Tetravac™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Tetravac™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).